Monitor early TRUTAKNA prescription/ revenue data over the next 2-4 quarters to gauge commercial traction. The key near-term catalysts are the ORIGIN 3 final efficacy analysis (Q3 2026), which could support full approval and label expansion, and the sBLA submission (Q4 2026). Given the stock's recent volatility (last 3 reports had large negative T+20 moves), the approval was already priced in, so focus on execution risk.
Price Chart
Executive Summary
Vera Therapeutics reported Q2 2026 earnings: net loss of $109.5M ($1.52/share) vs. $76.5M ($1.20/share) in Q2 2025, with operating cash burn of $206.8M in H1 2026. The FDA granted accelerated approval for TRUTAKNA (atacicept) in July 2026 for IgA nephropathy, and the U.S. commercial launch is underway. However, the company had no revenue, cash declined to $499.2M from $714.6M at year-end, and the per-share loss widened. The approval is a transformative event but the stock had already moved on the PDUFA date of July 7, 2026, so this filing itself is primarily an update on launch execution and financials.
Key Financial Metrics
Key Facts
- TRUTAKNA (atacicept) received FDA accelerated approval in July 2026 for primary IgA nephropathy; U.S. commercial launch is underway.
- Q2 2026 net loss of $109.5M, or $1.52 per share, vs. $76.5M, or $1.20 per share, in Q2 2025.
- Cash, cash equivalents, and marketable securities were $499.2M at June 30, 2026, plus up to $425M available under a debt facility.
- FDA alignment on earlier ORIGIN 3 final efficacy analysis to support potential full approval; results expected Q3 2026.
- Net cash used in operating activities was $206.8M for the six months ended June 30, 2026, vs. $109.2M for the same period in 2025.
- No revenue reported (pre-commercialization stage).
Financial Impact
Net loss of $109.5M in Q2 2026, widening from $76.5M in Q2 2025. Cash burn accelerated to $206.8M in H1 2026 from $109.2M in H1 2025. Despite the drug launch, cash declined by $215.4M from year-end 2025.
Risk Factors
- Commercial launch of TRUTAKNA may underperform expectations; patient uptake is unproven.
- Full approval of TRUTAKNA is contingent on positive ORIGIN 3 confirmatory data.
- Cash burn rate is high ($206.8M in H1); additional financing may be needed despite $499.2M cash + $425M debt facility.
- Competition in IgAN from other therapies (e.g., Tarpeyo, Filspari, and other BAFF/APRIL inhibitors in development).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342335 |
| Document: vera-20260810.htm | 0001193125-26-342335 |
| Document: 0001193125-26-342335-index-headers.html | 0001193125-26-342335 |
| Document: 0001193125-26-342335-index.html | 0001193125-26-342335 |
| Document: 0001193125-26-342335.txt | 0001193125-26-342335 |
| 8-K Data (Synthetic) | 0001193125-26-342335 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $33.67 $34.00 | ▲ +0.98% | ▲ +0.16% | $30.13 (−10.53%) |
Aug 10, 2026 7w ago | 8-K | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Aug 10, 2026 7w ago | Press Release | $30.29 $32.28 | ▲ +6.57% | ▲ +6.97% | $30.13 (−0.54%) |
Jul 9, 2026 12w ago | 8-K | $42.45 $39.12 | ▼ −7.84% | ▼ −7.71% | $30.13 (−29.03%) |
Jul 7, 2026 12w ago | 8-K | $42.96 $43.13 | ▲ +0.40% | ▼ −0.16% | $30.13 (−29.88%) |
Jun 11, 2026 16w ago | Institutional Cluster | $33.65 $35.01 | ▲ +4.04% | ▲ +3.61% | $30.13 (−10.48%) |
Jun 2, 2026 17w ago | 8-K | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
Jun 2, 2026 17w ago | Press Release | $31.26 $31.81 | ▲ +1.76% | ▲ +4.72% | $30.13 (−3.63%) |
May 7, 2026 21w ago | 8-K | $35.88 $39.15 | ▲ +9.11% | ▲ +7.61% | $30.13 (−16.04%) |
Feb 26, 2026 31w ago | 8-K | $42.35 $38.85 | ▼ −8.26% | ▼ −7.14% | $30.13 (−28.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access